Nektar Therapeutics (ITH0)

Currency in EUR
21.80
+0.40(+1.87%)
Delayed Data·
ITH0 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
21.8021.80
52 wk Range
0.4032.30
Key Statistics
Bid/Ask
21.40 / 21.60
Prev. Close
21.4
Open
21.8
Day's Range
21.8-21.8
52 wk Range
0.4-32.3
Volume
5
Average Volume (3m)
4.07K
1-Year Change
1,530.09%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ITH0 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Nektar Therapeutics News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Compare ITH0 to Peers and Sector

Metrics to compare
ITH0
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x0.0x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x0.0x
Price / LTM Sales
0.0x0.0x0.0x
Upside (Analyst Target)
0.0%0.0%0.0%
Fair Value Upside
Unlock0.0%0.0%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ITH0 Income Statement

People Also Watch

40.17
BMNR
+0.93%
7.145
BBAI
-3.32%
61.72
MP
-0.58%
1.69
WOLF
+2.74%
50.745
SMR
-1.79%

FAQ

What Stock Exchange Does Nektar Therapeutics Trade On?

Nektar Therapeutics is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Nektar Therapeutics?

The stock symbol for Nektar Therapeutics is "ITH0."

What Is the Nektar Therapeutics Market Cap?

As of today, Nektar Therapeutics market cap is 369.25M.

What Is Nektar Therapeutics's Earnings Per Share (TTM)?

The Nektar Therapeutics EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is ITH0 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Nektar Therapeutics Stock Split?

Nektar Therapeutics has split 0 times.

What is the current trading status of Nektar Therapeutics (ITH0)?

As of 28 Jul 2025, Nektar Therapeutics (ITH0) is trading at a price of 21.80, with a previous close of 21.40. The stock has fluctuated within a day range of 21.80 to 21.80, while its 52-week range spans from 0.40 to 32.30.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.